Sanofi has been boosted by the news that the US Food and Drug Administration has approved Toujeo, the follow-up to its diabetes blockbuster Lantus.

Toujeo (insulin glargine [rDNA origin] injection 300 U/mL), a once-daily long-acting basal insulin, has been given the green light to improve glycaemic control in adults living with type 1 and type 2 diabetes. It is expected to be available in the USA at the beginning of the second quarter.

The approval is based on the EDITION Phase III programme, which compared Toujeo in more than 3,500 adults with once-daily Lantus (insulin glargine [rDNA origin] injection, 100 U/mL). It demonstrated similar blood glucose control as Lantus but significantly lower rates of hypoglycaemia,
 
Sanofi quoted John Anderson from the Frist Clinic of Nashville (and past president of the American Diabetes Association) as saying that nearly 50% of people living with the disease remain uncontrolled. He added that “despite the proven efficacy of insulin, ensuring effective titration and maintenance can be a challenge [and] Toujeo provides a new option”.